12.2 Infection & Tumor Imaging with Special Radiopharmaceuticals

12.2 Infection & Tumor Imaging with Special Radiopharmaceuticals

Quick Answer: While F-18 FDG is the workhorse of PET imaging, certain specialized radiopharmaceuticals are essential for targeting specific cellular mechanisms. Gallium-67 citrate targets inflammation and specific tumors (like lymphoma) via transferrin pathways. Indium-111 and Tc-99m labeled leukocytes (WBCs) are the gold standard for acute bacterial infections. Meanwhile, somatostatin receptor-based agents (In-111 pentetreotide, Ga-68 Dotatate) and PSMA-targeted agents are critical for imaging neuroendocrine tumors and prostate cancer, respectively.

1. Gallium-67 Citrate

Gallium-67 (Ga-67) citrate is a cyclotron-produced radiopharmaceutical historically used for both infection/inflammation and tumor imaging. Ga-67 decays by electron capture with a physical half-life of 78.3 hours, emitting four primary gamma photons (93, 184, 300, and 393 keV).

Mechanism of Localization

Once injected intravenously, Ga-67 acts as an iron analog. It binds rapidly to the serum protein transferrin. Its localization at sites of infection or malignancy is driven by several mechanisms:

• Increased capillary permeability: Inflammatory processes allow the Ga-67-transferrin complex to leak into the interstitial space.
• Lactoferrin binding: At infection sites, activated neutrophils release lactoferrin, which has a higher affinity for Ga-67 than transferrin. The Ga-67 transfers to lactoferrin and becomes trapped within the inflammatory lesion.
• Direct cellular uptake: Certain tumor cells and bacteria express transferrin receptors on their surface, actively internalizing the Ga-67.

Clinical Indications

While largely replaced by F-18 FDG PET for many oncological indications, Ga-67 is still utilized for specific scenarios:

• Tumor Imaging: Specifically for Hodgkin's and non-Hodgkin's lymphoma, and occasionally for hepatoma.
• Infection/Inflammation: It is particularly useful for detecting chronic infections, opportunistic infections (such as Pneumocystis jirovecii pneumonia in immunocompromised patients), and granulomatous diseases like sarcoidosis. In sarcoidosis, characteristic bilateral hilar and right paratracheal lymph node uptake is often seen (the "lambda" sign), along with lacrimal and salivary gland uptake (the "panda" sign).

Imaging Considerations

Due to its relatively slow clearance from the blood and accumulation in target tissues, imaging is typically delayed. Tumor imaging is usually performed at 48 to 72 hours post-injection, while infection imaging may begin at 24 hours. The normal biodistribution includes the liver, bone marrow, spleen, and significant bowel excretion, which often necessitates the use of laxatives to clear background abdominal activity.

2. Labeled Leukocytes (WBCs)

For the detection of acute bacterial infections, radiolabeled white blood cells (leukocytes) are considered the gold standard. They provide higher specificity than Ga-67, particularly in the abdomen, because they do not normally undergo bowel excretion.

The Labeling Process

Radiolabeling WBCs requires drawing a large sample of the patient's blood (typically 40-60 mL) and performing an in vitro cell separation in a sterile hood. The blood is centrifuged to isolate the leukocyte-rich plasma. The isolated WBCs are then incubated with a lipophilic radiotracer—either In-111 oxine or Tc-99m HMPAO (exametazime). The lipophilic complex passively diffuses across the WBC membrane, where it becomes trapped. The labeled cells are washed, resuspended, and carefully reinjected into the patient.

Indium-111 Oxine vs. Tc-99m HMPAO

• In-111 Oxine: Has a physical half-life of 67 hours and emits gamma rays at 171 and 245 keV. Its longer half-life allows for delayed imaging at 24 hours, making it ideal for suspected osteomyelitis, intra-abdominal abscesses, and evaluating vascular graft infections. Normal distribution includes the spleen (most intense), liver, and bone marrow.
• Tc-99m HMPAO: With a 6-hour half-life, this agent requires earlier imaging (usually 1 to 4 hours post-injection). It provides superior image quality due to the ideal 140 keV energy of Tc-99m and the ability to inject a higher dose. It is primarily used for diagnosing inflammatory bowel disease (IBD) and acute infections in pediatric patients.

3. Neuroendocrine Tumor (NET) Imaging

Neuroendocrine tumors (such as carcinoids, gastrinomas, and paragangliomas) originate from the endocrine and nervous systems. A hallmark of these tumors is the over-expression of somatostatin receptors on their cell membranes.

In-111 Pentetreotide (Octreoscan)

Pentetreotide is a synthetic analog of the hormone somatostatin. When labeled with In-111, it binds specifically to somatostatin receptors (primarily subtypes 2 and 5) found on NETs.

• Imaging Protocol: Following injection, planar and SPECT imaging are typically performed at 4 hours and 24 hours. A mild laxative may be prescribed to clear hepatobiliary excretion from the bowel.
• Normal Biodistribution: Intense normal uptake is seen in the spleen, kidneys, liver, and urinary bladder. The thyroid and pituitary glands may also be faintly visualized.

Ga-68 Dotatate PET/CT

Ga-68 Dotatate has largely superseded In-111 Octreoscan at modern facilities. Dotatate is a peptide that binds with extremely high affinity to somatostatin receptor subtype 2.

• Advantages: Labeled with the positron emitter Gallium-68 (half-life of 68 minutes), Ga-68 Dotatate utilizes PET technology. This provides vastly superior spatial resolution, earlier imaging times (typically 45-60 minutes post-injection), and improved sensitivity for detecting small metastases compared to the traditional In-111 SPECT scan.

4. Prostate-Specific Membrane Antigen (PSMA) Imaging

Prostate cancer cells vastly over-express a transmembrane protein called Prostate-Specific Membrane Antigen (PSMA). Normal prostate tissue expresses PSMA at very low levels, while prostate cancer lesions express it at levels 100 to 1,000 times higher.

Ga-68 and F-18 Labeled PSMA Agents

Radiopharmaceuticals such as Ga-68 PSMA-11 and F-18 piflufolastat (Pylarify) are designed to bind specifically to the extracellular domain of the PSMA protein.

• Clinical Utility: These agents have revolutionized prostate cancer management. They are indicated for patients with suspected metastasis who are candidates for initial definitive therapy, and for patients with suspected recurrence based on elevated serum PSA levels.
• Normal Biodistribution: Normal, intense uptake is seen in the lacrimal glands, salivary glands, liver, spleen, kidneys, and small bowel. Intense activity in the ureters and bladder is also typical due to renal excretion.